ORGO
NASDAQ · Biotechnology
Organogenesis Holdings Inc
$2.47
+0.06 (+2.49%)
Open$2.48
Previous Close$2.41
Day High$2.50
Day Low$2.45
52W High$7.08
52W Low$2.61
Volume—
Avg Volume509.3K
Market Cap505.11M
P/E Ratio502.60
EPS$0.00
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+238.1% upside
Current
$2.47
$2.47
Target
$8.35
$8.35
$5.30
$8.35 avg
$10.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 455.46M | 451.04M | 163.70M |
| Net Income | 808.7K | 720.7K | 15.03M |
| Profit Margin | 0.2% | 0.2% | 9.2% |
| EBITDA | 11.68M | 10.99M | 20.76M |
| Free Cash Flow | — | — | 17.26M |
| Rev Growth | +1.0% | +1.0% | +17.3% |
| Debt/Equity | 0.00 | 0.00 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |